Published in Neoplasia on July 18, 2003
TGFbeta in Cancer. Cell (2008) 17.44
Distinct mechanisms of TGF-beta1-mediated epithelial-to-mesenchymal transition and metastasis during skin carcinogenesis. J Clin Invest (2005) 1.98
Survey of differentially methylated promoters in prostate cancer cell lines. Neoplasia (2005) 1.63
BMP7, a putative regulator of epithelial homeostasis in the human prostate, is a potent inhibitor of prostate cancer bone metastasis in vivo. Am J Pathol (2007) 1.58
Modeling prostate cancer in mice: something old, something new, something premalignant, something metastatic. Cancer Metastasis Rev (2013) 1.08
Stroma-epithelium crosstalk in prostate cancer. Asian J Androl (2008) 1.07
Dysfunctional transforming growth factor-beta receptor II accelerates prostate tumorigenesis in the TRAMP mouse model. Cancer Res (2009) 1.04
A microRNA gene expression signature predicts response to erlotinib in epithelial cancer cell lines and targets EMT. Br J Cancer (2011) 1.03
Cathepsin B is the driving force of esophageal cell invasion in a fibroblast-dependent manner. Neoplasia (2010) 0.98
Androgenic control of transforming growth factor-beta signaling in prostate epithelial cells through transcriptional suppression of transforming growth factor-beta receptor II. Cancer Res (2008) 0.96
Mouse models of prostate cancer: picking the best model for the question. Cancer Metastasis Rev (2014) 0.93
Molecular signatures of the primitive prostate stem cell niche reveal novel mesenchymal-epithelial signaling pathways. PLoS One (2010) 0.92
Network-based prediction for sources of transcriptional dysregulation using latent pathway identification analysis. Proc Natl Acad Sci U S A (2011) 0.90
Endoglin phosphorylation by ALK2 contributes to the regulation of prostate cancer cell migration. Carcinogenesis (2009) 0.89
TGFbeta signaling supports survival and metastasis of endometrial cancer cells. Cancer Manag Res (2009) 0.84
Gene targeting to the stroma of the prostate and bone. Differentiation (2008) 0.84
Prostate cancer: the need for biomarkers and new therapeutic targets. J Zhejiang Univ Sci B (2014) 0.82
Prostate cancer induced by loss of Apc is restrained by TGFβ signaling. PLoS One (2014) 0.79
4C-seq revealed long-range interactions of a functional enhancer at the 8q24 prostate cancer risk locus. Sci Rep (2016) 0.79
PIAS1-modulated Smad2/4 complex activation is involved in zinc-induced cancer cell apoptosis. Cell Death Dis (2013) 0.78
A review of the past, present, and future directions of neoplasia. Neoplasia (2005) 0.77
Local microenvironment provides important cues for cell differentiation in lingual epithelia. PLoS One (2012) 0.77
MicroRNA and Transcription Factor Gene Regulatory Network Analysis Reveals Key Regulatory Elements Associated with Prostate Cancer Progression. PLoS One (2016) 0.75
SFMBT2 (Scm-like with four mbt domains 2) negatively regulates cell migration and invasion in prostate cancer cells. Oncotarget (2016) 0.75
Gene expression correlates of clinical prostate cancer behavior. Cancer Cell (2002) 16.27
TGF-beta signaling in tumor suppression and cancer progression. Nat Genet (2001) 11.64
TGF-beta signaling blockade inhibits PTHrP secretion by breast cancer cells and bone metastases development. J Clin Invest (1999) 5.30
Expression of a truncated, kinase-defective TGF-beta type II receptor in mouse skeletal tissue promotes terminal chondrocyte differentiation and osteoarthritis. J Cell Biol (1997) 2.72
Modulation of type beta transforming growth factor activity in bone cultures by osteotropic hormones. Proc Natl Acad Sci U S A (1987) 2.29
Promoter deletion and loss of retinoblastoma gene expression in human prostate carcinoma. Proc Natl Acad Sci U S A (1990) 1.82
A probasin-large T antigen transgenic mouse line develops prostate adenocarcinoma and neuroendocrine carcinoma with metastatic potential. Cancer Res (2001) 1.59
Expression of a dominant-negative type II transforming growth factor beta (TGF-beta) receptor in the epidermis of transgenic mice blocks TGF-beta-mediated growth inhibition. Proc Natl Acad Sci U S A (1997) 1.47
Development, progression, and androgen-dependence of prostate tumors in probasin-large T antigen transgenic mice: a model for prostate cancer. Lab Invest (1998) 1.35
Specificity in transforming growth factor beta-induced transcription of the plasminogen activator inhibitor-1 gene: interactions of promoter DNA, transcription factor muE3, and Smad proteins. Proc Natl Acad Sci U S A (1999) 1.30
Regulation of plasminogen activator inhibitor-1 expression by transforming growth factor-beta -induced physical and functional interactions between smads and Sp1. J Biol Chem (2000) 1.25
Increased smad expression and activation are associated with apoptosis in normal and malignant prostate after castration. Cancer Res (1999) 1.18
Can radical prostatectomy alter the progression of poorly differentiated prostate cancer? J Urol (1994) 1.18
Expression of plasminogen activator inhibitor type 1 by human prostate carcinoma cells inhibits primary tumor growth, tumor-associated angiogenesis, and metastasis to lung and liver in an athymic mouse model. J Clin Invest (1995) 1.17
Large fragment of the probasin promoter targets high levels of transgene expression to the prostate of transgenic mice. Prostate (1997) 1.15
Transdifferentiation of NRP-152 rat prostatic basal epithelial cells toward a luminal phenotype: regulation by glucocorticoid, insulin-like growth factor-I and transforming growth factor-beta. J Cell Sci (1999) 1.15
Down-regulation of protein and mRNA expression for transforming growth factor-beta (TGF-beta1) type I and type II receptors in human prostate cancer. Int J Cancer (1997) 1.04
Prognostic significance of p53 nuclear accumulation in localized prostate cancer treated with radical prostatectomy. Cancer Res (2000) 1.02
Loss of expression of transforming growth factor-beta receptors is associated with poor prognosis in prostate cancer patients. Clin Cancer Res (1998) 0.97
Modulation of transforming growth factor beta 1 effects on prostate cancer cell proliferation by growth factors and extracellular matrix. Cancer Res (1995) 0.92
Diversity and modulation of plasminogen activator activity in human prostate carcinoma cell lines. Prostate (1995) 0.82
Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest (2011) 14.22
Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N Engl J Med (2012) 13.17
Stromal fibroblasts in cancer initiation and progression. Nature (2004) 11.69
TGF-beta signaling in fibroblasts modulates the oncogenic potential of adjacent epithelia. Science (2004) 10.23
Tumour microenvironment: TGFbeta: the molecular Jekyll and Hyde of cancer. Nat Rev Cancer (2006) 8.59
Expansion of myeloid immune suppressor Gr+CD11b+ cells in tumor-bearing host directly promotes tumor angiogenesis. Cancer Cell (2004) 7.61
Abrogation of TGF beta signaling in mammary carcinomas recruits Gr-1+CD11b+ myeloid cells that promote metastasis. Cancer Cell (2008) 6.78
Experimentally derived metastasis gene expression profile predicts recurrence and death in patients with colon cancer. Gastroenterology (2009) 4.08
Proteomic patterns of tumour subsets in non-small-cell lung cancer. Lancet (2003) 4.01
The pan-ErbB negative regulator Lrig1 is an intestinal stem cell marker that functions as a tumor suppressor. Cell (2012) 3.91
Hyperactivation of phosphatidylinositol-3 kinase promotes escape from hormone dependence in estrogen receptor-positive human breast cancer. J Clin Invest (2010) 3.53
TGF-beta and cancer. Cytokine Growth Factor Rev (2005) 3.38
Conditional inactivation of the TGF-beta type II receptor using Cre:Lox. Genesis (2002) 3.21
Aggressive pancreatic ductal adenocarcinoma in mice caused by pancreas-specific blockade of transforming growth factor-beta signaling in cooperation with active Kras expression. Genes Dev (2006) 3.16
The role of hepatocyte nuclear factor-3 alpha (Forkhead Box A1) and androgen receptor in transcriptional regulation of prostatic genes. Mol Endocrinol (2003) 3.01
Tumor-stroma interactions. Curr Opin Genet Dev (2005) 2.89
Conditional inactivation of Tgfbr2 in cranial neural crest causes cleft palate and calvaria defects. Development (2003) 2.78
Significance of p63 amplification and overexpression in lung cancer development and prognosis. Cancer Res (2003) 2.70
Effect of conditional knockout of the type II TGF-beta receptor gene in mammary epithelia on mammary gland development and polyomavirus middle T antigen induced tumor formation and metastasis. Cancer Res (2005) 2.63
The relationship between dose of vitamin E and suppression of oxidative stress in humans. Free Radic Biol Med (2007) 2.62
TGF-beta and immune cells: an important regulatory axis in the tumor microenvironment and progression. Trends Immunol (2010) 2.61
Activation of the Erk pathway is required for TGF-beta1-induced EMT in vitro. Neoplasia (2004) 2.60
Essential role of Smad3 in angiotensin II-induced vascular fibrosis. Circ Res (2006) 2.59
Inhibiting Cxcr2 disrupts tumor-stromal interactions and improves survival in a mouse model of pancreatic ductal adenocarcinoma. J Clin Invest (2011) 2.54
Plasma cytokine levels predict mortality in patients with acute renal failure. Kidney Int (2004) 2.52
Inhibition of TGF-beta with neutralizing antibodies prevents radiation-induced acceleration of metastatic cancer progression. J Clin Invest (2007) 2.52
Loss of TGF-beta type II receptor in fibroblasts promotes mammary carcinoma growth and invasion through upregulation of TGF-alpha-, MSP- and HGF-mediated signaling networks. Oncogene (2005) 2.35
The roles of TGFβ in the tumour microenvironment. Nat Rev Cancer (2013) 2.35
Induction by transforming growth factor-beta1 of epithelial to mesenchymal transition is a rare event in vitro. Breast Cancer Res (2004) 2.33
A tale of two proteins: differential roles and regulation of Smad2 and Smad3 in TGF-beta signaling. J Cell Biochem (2007) 2.32
Forkhead box A1 regulates prostate ductal morphogenesis and promotes epithelial cell maturation. Development (2005) 2.31
Prostate cancer cells with stem cell characteristics reconstitute the original human tumor in vivo. Cancer Res (2007) 2.22
A genome-wide screen for promoter methylation in lung cancer identifies novel methylation markers for multiple malignancies. PLoS Med (2006) 2.16
Transforming growth factor beta receptor type II inactivation induces the malignant transformation of intestinal neoplasms initiated by Apc mutation. Cancer Res (2006) 2.14
Short preoperative treatment with erlotinib inhibits tumor cell proliferation in hormone receptor-positive breast cancers. J Clin Oncol (2008) 2.10
Evaluating markers for the early detection of cancer: overview of study designs and methods. Clin Trials (2006) 2.10
Proteomic-based prognosis of brain tumor patients using direct-tissue matrix-assisted laser desorption ionization mass spectrometry. Cancer Res (2005) 2.06
Gene expression differences associated with human papillomavirus status in head and neck squamous cell carcinoma. Clin Cancer Res (2006) 2.05
Increased malignancy of Neu-induced mammary tumors overexpressing active transforming growth factor beta1. Mol Cell Biol (2003) 1.99
Expression and role of Foxa proteins in prostate cancer. Prostate (2006) 1.96
Transforming growth factor beta (TGF-beta) and inflammation in cancer. Cytokine Growth Factor Rev (2009) 1.95
Hepsin promotes prostate cancer progression and metastasis. Cancer Cell (2004) 1.89
Molecular alterations in primary prostate cancer after androgen ablation therapy. Clin Cancer Res (2005) 1.88
The receptor tyrosine kinase inhibitor SU11248 impedes endothelial cell migration, tubule formation, and blood vessel formation in vivo, but has little effect on existing tumor vessels. Angiogenesis (2004) 1.87
Gr-1+CD11b+ myeloid cells tip the balance of immune protection to tumor promotion in the premetastatic lung. Cancer Res (2010) 1.83
Transcriptional cooperation between the transforming growth factor-beta and Wnt pathways in mammary and intestinal tumorigenesis. Cancer Res (2007) 1.81
Regulation of heparin-binding EGF-like growth factor by miR-212 and acquired cetuximab-resistance in head and neck squamous cell carcinoma. PLoS One (2010) 1.77
The nuclear factor-kappaB pathway controls the progression of prostate cancer to androgen-independent growth. Cancer Res (2008) 1.76
ERα-dependent E2F transcription can mediate resistance to estrogen deprivation in human breast cancer. Cancer Discov (2011) 1.76
Foxa1 and Foxa2 interact with the androgen receptor to regulate prostate and epididymal genes differentially. Ann N Y Acad Sci (2005) 1.75
TNBCtype: A Subtyping Tool for Triple-Negative Breast Cancer. Cancer Inform (2012) 1.72
TGF-beta receptor deletion in the renal collecting system exacerbates fibrosis. J Am Soc Nephrol (2010) 1.70
Cytosolic and nuclear protein targets of thiol-reactive electrophiles. Chem Res Toxicol (2006) 1.69
Abrogation of TGF-beta signaling enhances chemokine production and correlates with prognosis in human breast cancer. J Clin Invest (2009) 1.68
Influence of initiation of maintenance hemodialysis on biomarkers of inflammation and oxidative stress. Kidney Int (2004) 1.66
Transforming growth factor-beta regulates mammary carcinoma cell survival and interaction with the adjacent microenvironment. Cancer Res (2008) 1.64
Loss of the urothelial differentiation marker FOXA1 is associated with high grade, late stage bladder cancer and increased tumor proliferation. PLoS One (2012) 1.63
Genetic disease in the children of Danish survivors of childhood and adolescent cancer. J Clin Oncol (2011) 1.63
Effects of intercellular adhesion molecule 1 (ICAM-1) null mutation on radiation-induced pulmonary fibrosis and respiratory insufficiency in mice. J Natl Cancer Inst (2002) 1.63
Altered TGF-β signaling in a subpopulation of human stromal cells promotes prostatic carcinogenesis. Cancer Res (2011) 1.62
Transforming growth factor beta receptor type II inactivation promotes the establishment and progression of colon cancer. Cancer Res (2004) 1.62
Comparative study of exome copy number variation estimation tools using array comparative genomic hybridization as control. Biomed Res Int (2013) 1.61
Bone morphogenetic protein 4 promotes pulmonary vascular remodeling in hypoxic pulmonary hypertension. Circ Res (2005) 1.61
Large scale comparison of gene expression levels by microarrays and RNAseq using TCGA data. PLoS One (2013) 1.61
Impaired tumor microenvironment in EphA2-deficient mice inhibits tumor angiogenesis and metastatic progression. FASEB J (2005) 1.61
Large oncosomes in human prostate cancer tissues and in the circulation of mice with metastatic disease. Am J Pathol (2012) 1.60
DC isoketal-modified proteins activate T cells and promote hypertension. J Clin Invest (2014) 1.59
Unopposed c-MYC expression in benign prostatic epithelium causes a cancer phenotype. Prostate (2005) 1.57
Global shifts in protein sumoylation in response to electrophile and oxidative stress. Chem Res Toxicol (2004) 1.57
Polymorphisms in human organic anion-transporting polypeptide 1A2 (OATP1A2): implications for altered drug disposition and central nervous system drug entry. J Biol Chem (2005) 1.56
Effect of IGF-I in the chondrogenesis of bone marrow mesenchymal stem cells in the presence or absence of TGF-beta signaling. J Bone Miner Res (2006) 1.55
Evidence Combination From an Evolutionary Game Theory Perspective. IEEE Trans Cybern (2015) 1.54
Recruitment of bone marrow derived cells to the bladder after bladder outlet obstruction. J Urol (2009) 1.54
An allograft model of androgen independent prostatic neuroendocrine carcinoma derived from a large probasin promoter-T antigen transgenic mouse line. J Urol (2004) 1.53
A kinome-wide screen identifies the insulin/IGF-I receptor pathway as a mechanism of escape from hormone dependence in breast cancer. Cancer Res (2011) 1.53
Genetic and clinical predictors for breast cancer risk assessment and stratification among Chinese women. J Natl Cancer Inst (2010) 1.51
TGF-beta signaling is essential for joint morphogenesis. J Cell Biol (2007) 1.51
Development and characterization of efficient xenograft models for benign and malignant human prostate tissue. Prostate (2005) 1.49